# Jaguar Health Targets Mid-2027 MVID Filing After More Than $10 Million in Debt Reduction

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/59649
Published: 2026-11-17T17:03:19.000Z
Updated: 2026-11-17T17:03:19.000Z
Section: Business

> Participants in the pivotal pediatric MVID trial have entered extension dosing. Jaguar also plans to seek breakthrough therapy designation in 2027.

Jaguar Health is targeting a mid-2027 new drug application submission for crofelemer to treat pediatric MVID after completing pivotal-trial enrollment, with participants now in extension dosing.

Jaguar plans to seek breakthrough therapy designation in 2027. The designation could potentially enable a four-month Food and Drug Administration review.

The company reduced its outstanding debt by more than $10 million in Q3 2026. The update adds clinical and debt milestones to Jaguar’s [quarterly results](<https://www.tokenpost.com/news/business/58474>), which included $2.343 million in revenue and a $9.23 net loss per share.

Jaguar’s prescription product net revenue was about $500,000 in Q3 2026, compared with about $1.2 million in Q2 2026. U.S. revenue from Mytesi and Canalevia-CA1 has been directed to Future Pak since Jan. 12, 2026. Jaguar supplies the products under cost-plus terms.

The company’s next stated milestone is its targeted mid-2027 NDA submission.



## Links in this article

- [quarterly results](https://www.tokenpost.com/news/business/58474)
